Per la versione in italiano, vogliate seguire questo link. Lugano, Switzerland, December 6, 2021 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with […]

Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record […]

The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs BridgeBio […]

Update to PR: The exclusive license granted by Helsinn to Fosun Pharmaceutical AG with respect to Akynzeo® oral in Hong Kong SAR and Macau SAR […]

Lugano, Switzerland, 7 October 2021 – Helsinn Group, a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically […]

– Health Canada Issues Conditional Approval of TRUSELTIQ under Project Orbis (September 27th, 2021) LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 – Helsinn […]

Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical Group with an innovative R&D pipeline in cancer supportive care and oncology therapeutics, strategically investing […]

Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring […]

May 27, 2021 – Taiho Pharmaceutical Co., Ltd.  and Helsinn Healthcare SA, which is headquartered in Lugano, Switzerland , announced today that Taiho has acquired […]

Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce […]